Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd: Strengths and Weaknesses

Highlights: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 69.47 times its estimated earnings per share for the ongoing year.
  • The company appears highly valued given the size of its balance sheet.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd SectorChina

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd SectorChina

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd SectorChina

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
6.71B - - - - -
72.52B
BBB
52.9B
AA
45.93B
BBB
35.49B
A
29.22B
AA
20.98B -
BBB
- -
19.56B
AAA
20.04B
AA
16.66B
AA
Average 32B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. 688336 Stock
  4. Ratings Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd